-
1 Comment
Kissei Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 3.8% below its 200 day moving average.
From a valuation standpoint, the stock is 97.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.7.
Kissei Pharmaceutical Co., Ltd's total revenue rose by 17.1% to $20B since the same quarter in the previous year.
Its net income has increased by 46.8% to $2B since the same quarter in the previous year.
Based on the above factors, Kissei Pharmaceutical Co., Ltd gets an overall score of 3/5.
Exchange | TSE |
---|---|
CurrencyCode | JPY |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
ISIN | JP3240600001 |
Market Cap | 165B |
---|---|
PE Ratio | 14.06 |
Target Price | 4175 |
Dividend Yield | 3.0% |
Beta | -0.12 |
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Kalogra tablets, for the treatment of ulcerative colitis; Tabuneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Malizeb tablets; Tavaris tablets for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. Its products in pipeline include CG0070, which is in Phase III clinical trial to treat non-muscle-invasive bladder cancer; Linzagolix, which is in Phase III clinical trial for the treatment of uterine fibroids and endometriosis; KDT-3594, which is in Phase II clinical trial to treat Parkinson's disease; KSP-0243 that is in Phase II clinical trial to treat Ulcerative colitis; and Difelikefalin, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. The company is also developing Silodosin for dysuria associated with benign prostatic hyperplasia; and Fostamatinib for tyrosine kinase inhibitor. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, facility and equipment management, and information gathering and development support services. Further, the company engages in the information equipment rentals; insurance agency business; manufactures and sells noodles; and undertakes construction of factories, research institutes, offices, etc., as well as computer system design and development, and cloud services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was incorporated in 1946 and is headquartered in Matsumoto, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4547.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025